Carrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable CNLC Stage IIa/IIb Hepatocellular Carcinoma

Clinical Trial ID NCT04521153

Rank	Title	Journal	Year	PubWeight™‹?›
1	Global cancer statistics, 2012.	CA Cancer J Clin	2015	53.52
2	Cancer statistics in China, 2015.	CA Cancer J Clin	2016	12.92
3	Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2).	Lancet	2014	8.59
4	Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.	Lancet	2000	4.60
5	Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.	Gastroenterology	2015	3.04
6	Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.	Lancet Oncol	2015	1.66
7	Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma.	Clin Cancer Res	2004	1.23
8	Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: A pilot study.	Hepatol Res	2013	0.94
9	Tumor vaccine against recurrence of hepatocellular carcinoma.	World J Gastroenterol	2005	0.78